Read by QxMD icon Read

peginterferon alpha 2a

Nipun Verma, Shreya Singh, Gitesh Sawatkar, Virendra Singh
Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious, dermatologic, adverse effect following the use of sofosbuvir. A 35-year-old man with genotype 3-related HCV cirrhosis presented with decompensated ascites and jaundice following 7 weeks of therapy with peginterferon alpha-2a and oral ribavirin. After peginterferon withdrawal and stabilization, oral sofosbuvir and ribavirin were started; 10 days later, he developed itching over the trunk and legs, followed by multiple papules and vesicles over an erythematous base...
January 2018: Hepatology Communications
Michael Gschwantler, Hermann Laferl, Wolfgang Vogel, Wolfgang Korak, Stephan Moser, Harald Hofer, Bernhard Bauer, Michael Schleicher, Barbara Bognar, Martin Bischof, Rudolf Stauber, Andreas Maieron, Peter Ferenci
BACKGROUND: Patients with a history of intravenous drug abuse included in an official opioid substitution program represent an important subgroup of patients with chronic hepatitis C. The objective of this study was to assess the efficacy of and adherence to treatment with peginterferon and ribavirin in Austrian patients on stable opioid substitution therapy (OST). METHODS: This prospective, multicenter, observational, non-interventional trial (clinicaltrials...
September 12, 2017: Wiener Klinische Wochenschrift
Julien Hadoux, Marie Terroir, Sophie Leboulleux, Frederic Deschamps, Abir Al Ghuzlan, Ségolène Hescot, Lambros Tselikas, Isabelle Borget, Caroline Caramella, Desirée Déandréis, Diane Goere, Thierry De Baere, Martin Schlumberger, Eric Baudin
Interferon-alpha (IFN-alpha) is recommended in neuroendocrine tumors (NET). Malignant pheochromocytoma and paragangliomas (MPPGLs) constitute a rare subgroup of NET with few treatment options. IFN-alpha efficacy in patients with MPPGLs was evaluated in a single-center retrospective study. Progression-free survival (PFS) was the primary endpoint according to RECIST 1.1 and/or PERCIST 1.0, and response rate, safety, and symptomatic efficacy were secondary endpoints. Fourteen patients received peginterferon alfa-2a (90 to 180 μg/week) or interferon alfa-2b (1...
December 2017: Hormones & Cancer
Ossama Ashraf Ahmed, Hany Haroun Kaisar, Nehad Hawash, Hossam Samir, Sherif Sadek Taha Shabana, Mohamed Hassan Ahmed Fouad, Fatma Rizk, Sherief Abd-Elsalam
Background &Aims: Sofosbuvir is a powerful drug for treatment of hepatitis C virus (HCV) infection. In comparison to preceding remedies, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and much lower duration of treatment. The aim of the work was to assess the efficacy and safety of sofosbuvir plus ribavirin with or without peginterferon-alfa in treatment of a cohort of Egyptian patients with hepatitis C virus infection. METHODS: Two hundred treatment naive patients who were HCV-antibody positive and HCV RNA by PCR positive aged more than 18 years were enrolled in the study and patients were classified into two groups: Group I which included 100 patients who received dual therapy with sofosbuvir plus oral weight based ribavirin and Group II which included 100 patients triple therapy with sofosbuvir plus oral weight based ribavirin (as with the dual therapy) and a 180 mcg Peg-INF alpha 2a subcutaneous injection weekly for 12 weeks...
April 17, 2017: Infectious Disorders Drug Targets
Liang-Jen Wang, Shuo-Wei Chen, Chih-Ken Chen, Cho-Li Yen, Jia-Jang Chang, Tsung-Shih Lee, Ching-Jung Liu, Li-Wei Chen, Rong-Nan Chien
BACKGROUND: This study investigates differences in depression and anxiety between patients with chronic hepatitis C who are treated with peginterferon alpha-2a (PegIFN-α-2a) plus ribavirin and those who are treated with peginterferon alpha-2b (PegIFN-α-2b) plus ribavirin. METHODS: In this 24 week, non-randomized, observational, prospective study, 55 patients with chronic hepatitis C were treated with PegIFN-α-2a plus ribavirin (Group 1), and 26 patients were treated with PegIFN-α-2b plus ribavirin (Group 2)...
November 25, 2016: BMC Psychiatry
Ka Zhang, Hong Cao, Jiayi Liang, Xin Shu, Haixia Sun, Gang Li, Qihuan Xu
BACKGROUND: The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D)...
August 2016: Medicine (Baltimore)
M Martinot-Peignoux, M Lapalus, S Maylin, N Boyer, C Castelnau, N Giuily, M Pouteau, R Moucari, T Asselah, P Marcellin
Quantitative hepatitis B core-related antigen (qHBcrAg) has been proposed as an additional marker to quantitative HBsAg (qHBsAg), for management of chronic hepatitis B. Evaluate baseline combination of qHBsAg and qHBcrAg for identification of patients that could benefit from pegylated interferon-alpha-2a (PegIFN)-based therapy. Sixty-two HBeAg-negative patients treated with PegIFN or PegIFN plus tenofovir disoproxil fumarate (PegIFN+TDF). HBsAg and HBcrAg titres were evaluated at baseline. Thirty patients received PegIFN and 32 PegIFN+TDF...
November 2016: Journal of Viral Hepatitis
María Buti, Raquel Domínguez-Hernández, Itziar Oyagüez, Miguel Ángel Casado
AIMS: Cost-effectiveness analysis of sofosbuvir combined with peginterferon alpha-2a and ribavirin (SOF/Peg-IFN/RBV) in early versus advanced fibrosis in previously untreated patients with chronic hepatitis C genotype 1 (CHC-GT1), from the perspective of the Spanish National Health System (NHS). METHODS: A Markov model was developed to compare lifetime costs and outcomes (life years gained [LYGs] and quality-adjusted life years [QALYs]) of 2 treatment strategies: SOF/Peg-IFN/RBV administered during early fibrosis (mild-moderate fibrosis; F2-F3) or advanced fibrosis (cirrhosis; F4)...
August 2016: Gastroenterología y Hepatología
Arturo Cortés-Telles
Pulmonary toxicity related to the use of pegylated interferon alpha-2a during treatment of hepatitis C infections is rare; nonetheless, some cases with fatal outcomes have been reported. Evaluating patients' pulmonary function is a key to diagnosis, follow-up and prognosis of several respiratory diseases, but case reports of respiratory manifestations related to the use of pegylated interferon alpha-2a have limited their findings to only baseline measurements. This paper examines the case of a 65-year-old woman with chronic hepatitis C virus infection who developed interstitial pneumonitis associated with pegylated interferon alpha-2a...
March 2016: Lung India: Official Organ of Indian Chest Society
Gamal Eldeen Esmat, Wafa Al Akel, Rasha Ahmed Abdel Aziz, Ahmed Al Sayed Taha, Dina Sabry, Laila A Rashed, Aya Mostafa, Amany Y El Kazaz, Sahar H Ahmed
The aim of this study was to determine the relative importance of the kinetics of antiviral response compared to baseline host and virological factors for predicting treatment outcome. A retrospective analysis of 285 chronic hepatitis C virus (HCV) patients, encompassing genotypes 4 treated with peginterferon alpha-2a and ribavirin, was performed. Baseline characteristics were compared across HCV genotypes and pretreatment factors associated with rapid virological response (RVR) were identified. The relative significance of RVR compared to other baseline factors for predicting sustained virological response was analyzed by multiple logistic regression analysis...
March 2016: Journal of Interferon & Cytokine Research
Yunus Gürbüz, Necla Eren Tülek, Emin Ediz Tütüncü, Süda Tekin Koruk, Bilgehan Aygen, Neşe Demirtürk, Sami Kınıklı, Ali Kaya, Taner Yıldırmak, Kaya Süer, Fatime Korkmaz, Onur Ural, Sıla Akhan, Özgür Günal, Nazan Tuna, Şükran Köse, İbak Gönen, Bahar Örmen, Nesrin Türker, Neşe Saltoğlu, Ayşe Batırel, Günay Tuncer, Cemal Bulut, Fatma Sırmatel, Asım Ulçay, Ergenekon Karagöz, Derviş Tosun, Alper Şener, Aynur Aynıoğlu, Elif Sargın Altunok
BACKGROUND: Before the introduction of direct-acting antivirals in the treatment of chronic hepatitis C patients, the combination of peginterferon alpha and ribavirin was the standard therapy. Observational studies that investigated sustained virological response (SVR) rates by these drugs yielded different outcomes. AIMS: The goal of the study was to demonstrate real life data concerning SVR rate achieved by peginterferon alpha plus ribavirin in patients who were treatment-naïve...
January 2016: Balkan Medical Journal
Maissa El Raziky, Waleed Fouad Fathalah, Zeinab Zakaria, Hadeel Gamal Eldeen, Amr Abul-Fotouh, Ahmed Salama, Abubakr Awad, Gamal Esmat, Mahasen Mabrouk
Despite the appearance of new oral antiviral drugs, pegylated interferon (PEG-IFN)/RBV may remain the standard of care therapy for some time, and several viral and host factors are reported to be correlated with therapeutic effects. This study aimed to reveal the independent variables associated with failure of sustained virological response (SVR) to PEG-IFN alpha-2a versus PEG-IFN alpha-2b in treatment of naive chronic hepatitis C virus (HCV) Egyptian patients using both statistical methods and data mining techniques...
May 2016: Journal of Interferon & Cytokine Research
Lai Wei, Tao Han, Dongliang Yang, Jeong Heo, Jia Shang, Jun Cheng, Xinyue Chen, Qing Xie, Ju-Hyun Kim, Ronald Kalmeijer, Sivi Ouwerkerk-Mahadevan, Eva Hoeben, Oliver Lenz, Thierry Verbinnen, Rekha Sinha, MengChun Li, Jane Scott, Monika Peeters, James Witek
BACKGROUND AND AIM: Approximately one-third of patients with hepatitis C virus (HCV) genotype (GT) 1 infection live in East Asia. This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha-2a and ribavirin (PR) in HCV GT1-infected, treatment-naïve, Asian patients with compensated liver disease. METHODS: This phase III, randomized study (NCT01725529) was conducted in China and South Korea. Patients received simeprevir 150 mg once daily (QD), simeprevir 100 mg QD, or placebo, in combination with PR for 12 weeks...
May 2016: Journal of Gastroenterology and Hepatology
Pascal Veillon, Isabelle Fouchard-Hubert, Dominique Larrey, Manh Thông Dao, Louis D'alteroche, Nathalie Boyer-Darrigand, Nicolas Picard, Hélène Le Guillou-Guillemette, Patrick Saulnier, Alexandra Ducancelle, Véronique Loustaud-Ratti, Françoise Lunel-Fabiani
To investigate the impact of epoetin beta (EPO) on sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients treated with peginterferon-ribavirin (RBV). Controlled, randomized, pragmatic multicenter study to assess 2 strategies, ie, the use (EPO group) or nonuse (control group) of EPO in terms of achieving SVR in treatment-naive, genotype non-2/non-3 HCV-infected patients receiving a 48-week treatment regimen of pegylated interferon α-2a (peg-IFN) plus RBV (randomization 2:1). The single-nucleotide polymorphisms of interferon lambda 3 (IFNL3) (rs12979860 and rs8099917), interferon lambda 4 (IFNL4) (ss469415590), and inosine triphosphatase (ITPA) (rs1127354 and rs7270101) were determined retrospectively...
March 2016: Journal of Interferon & Cytokine Research
Mahdiyar Pouresmaeeli, Seyed Moayed Alavian, Maryam Keshvari, Shima Salimi, Leila Mehrnoush
BACKGROUND: Nearly 0.5% of Iranians are infected with HCV. Peginterferon-alpha-2a and Peginterferon-alpha-2b are the two available types of interferon for the treatment of hepatitis C. Comparing the results of these two treatments is still a challenge. OBJECTIVES: The aim of this study was to compare the results of Peginterferon-alpha-2a and Peginterferon-alpha-2b in Iranian patients with chronic hepatitis C. PATIENTS AND METHODS: 289 patients with chronic hepatitis C attending Tehran Hepatitis Center (THC) and Hepatitis Clinic of Tehran Blood Transfusion Organization (TBTO) from January 2008 to April 2013 and treated with combination of Peginterferon-alpha-2a or Peginterferon-alpha-2b plus Ribavirin were enrolled in this retrospective cross-sectional study...
September 2015: Hepatitis Monthly
Suzy Van Sanden, Marta Pisini, Inge Duchesne, Angelika Mehnert, Jonathan Belsey
BACKGROUND: The need to assess relative efficacy in the absence of comparative clinical trials is a problem that is often encountered in economic modeling. The use of matching adjusted indirect comparison (MAIC) in this situation has been suggested. We present the results of a MAIC used to evaluate the incremental benefit offered by adding simeprevir (SMV) to standard therapy in the treatment of patients infected with genotype 4 hepatitis C virus (HCV). METHODS: Individual patient data for a single arm study evaluating the use of SMV with peginterferon alfa 2a + ribavirin (PR) in genotype 4 HCV were available (RESTORE study)...
2016: Current Medical Research and Opinion
Patrick Marcellin, Sang Hoon Ahn, Xiaoli Ma, Florin A Caruntu, Won Young Tak, Magdy Elkashab, Wan-Long Chuang, Seng-Gee Lim, Fehmi Tabak, Rajiv Mehta, Joerg Petersen, Graham R Foster, Lillian Lou, Eduardo B Martins, Phillip Dinh, Lanjia Lin, Amoreena Corsa, Prista Charuworn, G Mani Subramanian, Hans Reiser, Hendrick W Reesink, Scott Fung, Simone I Strasser, Huy Trinh, Maria Buti, Giovanni B Gaeta, Aric J Hui, George Papatheodoridis, Robert Flisiak, Henry L Y Chan
BACKGROUND & AIMS: Patients chronically infected with the hepatitis B virus rarely achieve loss of serum hepatitis B surface antigen (HBsAg) with the standard of care. We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial. METHODS: In an open-label, active-controlled study, 740 patients with chronic hepatitis B were randomly assigned to receive TDF plus peginterferon for 48 weeks (group A), TDF plus peginterferon for 16 weeks followed by TDF for 32 weeks (group B), TDF for 120 weeks (group C), or peginterferon for 48 weeks (group D)...
January 2016: Gastroenterology
Ewa Janczewska, Robert Flisiak, Dorota Zarebska-Michaluk, Dorota Kozielewicz, Hanna Berak, Beata Dobracka, Marta Librant-Suska, Wladyslaw Lojewski, Krzysztof Jurczyk, Joanna Musialik, Barbara Postawa-Klosińska, Jacek Wroblewski, Krystyna Augustyniak, Marek Dudziak, Iwona Olszok, Agata Ruszala, Arkadiusz Pisula, Tadeusz Lapinski, Wieslaw Kryczka, Andrzej Horban, Witold Dobracki
We investigated the safety, efficacy, and impact of ribavirin and peginterferon dose reduction on complete early virologic response and sustained virologic response (SVR) to triple therapy with telaprevir in treatment-experienced patients with advanced liver fibrosis.Treatment was initiated for 211 patients who failed treatment with peginterferon and ribavirin, with bridging fibrosis (F3, n = 68) or cirrhosis (F4, n = 143), including 103 (49%) null-responders (NR), 30 (14%) partial responders (PR), and 78 (37%) relapsers (REL)...
September 2015: Medicine (Baltimore)
Sufen Liu, Huanwei Zheng, Yan Huang, Bingshun Li, Zhenghong Dong
BACKGROUND AND OBJECTIVE: The covalently closed circular DNA (cccDNA), as the template of HBV transcription, plays a key role in the virus infection. The present study aimed to compare the effect of pegylated interferon (IFN)-α-2a with that of conventional IFN-α-2a on intrahepatic covalently closed circular (ccc)DNA in patients with chronic hepatitis B. METHODS: Seventy-six HBeAg-positive chronic hepatitis B patients were randomly divided into two groups (n=38): group A was treated with interferon alpha-2a (IFN-α-2a) and group B was treated with peginterferon alpha-2a (peg IFN-α-2a)...
June 2016: Clinics and Research in Hepatology and Gastroenterology
Wolf Peter Hofmann, Stefan Mauss, Thomas Lutz, Andreas Schober, Klaus Böker, Gero Moog, Axel Baumgarten, Heike Pfeiffer-Vornkahl, Ulrich Alshuth, Dietrich Hüppe, Heiner Wedemeyer, Michael P Manns, Eckart Schott
BACKGROUND AND AIMS: Individualization of treatment with peginterferon alfa and ribavirin in patients with chronic hepatitis C showed benefit in controlled trials and was implemented in treatment guidelines to increase response rates and to reduce side effects and costs. However, it is unknown whether individualization was adopted in routine daily practice and whether it translated into improved outcomes. METHODS: From a large noninterventional cohort study, clinical and virologic response data of 10,262 HCV patients who received peginterferon alfa-2a and ribavirin between 2003-2007 and 2008-2011 were analyzed...
2015: PloS One
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"